BeiGene’s TEVIMBRA gains approval for OSCC in Israel
The Israeli Ministry of Health (IL MOH) has approved BeiGene’s TEVIMBRA (tislelizumab) as a monotherapy to treat adults with unresectable or metastatic oesophageal squamous cell carcinoma (OSCC) who have previously undergone systemic chemotherapy. The …